Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

NCT00866736 is registered in ClinicalTrials.gov with Kanto CML Study Group as lead sponsor.

NCT NCT00866736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00866736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
Lead sponsor
Kanto CML Study Group
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
June 30, 2012
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia